



Final Appraisal Recommendation

Advice No: 1115 – May 2015

Beclometasone dipropionate/formoterol fumarate (Fostair®) 100/6 micrograms pressurised inhalation solution

Submission by Chiesi Ltd

Recommendation of AWMSG

Beclometasone dipropionate/formoterol fumarate (Fostair®) is recommended as an option for use within NHS Wales for the symptomatic treatment of patients with chronic obstructive pulmonary disease, with a FEV1 < 50% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2364), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Chiesi Ltd
Date of first issue	May 2015
Last reviewed	June 2018

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1115:
Beclometasone dipropionate/formoterol fumarate (Fostair®). 100/6 micrograms pressurised
inhalation solution. May 2015.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.